FDA warning flags rare sudden-vision-loss risk with GLP-1 drugs

FDA-ordered labeling reportedly warns of NAION, a rare condition that can cause sudden vision loss. Coverage repeats an analysis counting 10 cases among 78,217 GLP-1 recipients versus 5 among 56,036 comparators; this association does not establish causation or individual risk. Verify current FDA wording and primary evidence, and do not advise patients to stop treatment.